Browsing Tag
Immutep Limited
2 posts
Immutep (ASX: IMM) closing in on critical readout — biotech traders discuss risk vs reward heading into 2026
Immutep Limited surpasses 170 patients in its global Phase III NSCLC trial, setting up a 2026 futility readout that could redefine its immunotherapy pipeline.
Immutep completes patient enrolment for Phase II trial of eftilagimod alpha in metastatic breast cancer
Immutep Limited, a clinical-stage biotechnology company specializing in advanced LAG-3 immunotherapies, has announced the completion of patient enrolment…